# Media Future

> Media Future is a VC fund in Tokyo backing Medical, Biotechnology and Pharmaceutical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 4
- Last investment: May 2020
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.mf-j.co.jp/

Media Future is a group of communication technology professionals that works on connecting feelings and thoughts. The Tokyo, Tokyo-based company was established in 2013.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $38M–$78M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 75% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Genetics | 1 | 25% |
| Oncology | 1 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |
| Funding Round | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alivexis | Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus iscomprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms. | $25.5M | Series B | May 13, 2020 |  |
| HekaBio | HekaBio is a healthcare development, investment, and commercialization platform with experience in oncology, radiation, and cardiovascular therapies. They invest in innovations in oncology, radiation, and cardiovascular therapy and commercialization. HekaBio enables patients by accelerating access to global healthcare innovations. | $78.2M | Series A | Dec 07, 2018 |  |
| HACARUS | HACARUS is a provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus' proprietary AI engine is built using Sparse Modeling, anAI method that understands data like a human would - by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning. | $38.3M | Series A | Oct 05, 2018 |  |
| Jiksak Bioengineering | Jiksak Bioengineering is a biotechnology company. Jiksak Bioengineering provide an efficient screening service using a three-dimensional cell tissue "Nerve Organoid". We will mainly develop screening technologies specifically for neurodegenerative diseases and search for drugs that are effective for amyotrophic lateral sclerosis (ALS). | $24.1M |  | Feb 21, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [Essential Pharma](https://shizune.co/investors/profile/essential-pharma) — VC Fund, 4 deals together
- [Ohara Pharmaceutical](https://shizune.co/investors/profile/ohara-pharmaceutical) — VC Fund, 3 deals together
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund, 1 deal together
- [Capital Medica Ventures](https://shizune.co/investors/profile/capital-medica-ventures) — VC Fund, 1 deal together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 1 deal together
- [Innovation Engine](https://shizune.co/investors/profile/innovation-engine) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Medical Investors in Japan](https://shizune.co/investors/medical-investors-japan)
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)
- [Life Science Investors in Japan](https://shizune.co/investors/life-science-investors-japan)
- [Life Science VC Funds in Japan](https://shizune.co/investors/life-science-vc-funds-japan)

## FAQ

### What does Media Future invest in?

Media Future invests primarily in Medical, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Media Future's check size?

Media Future typically joins rounds of $38M–$78M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Media Future participates in.

### When did Media Future last invest?

The most recent investment recorded for Media Future closed in May 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co